Your browser doesn't support javascript.
loading
Novel spiroindoline quinazolinedione derivatives as anticancer agents and potential FLT3 kinase inhibitors.
Divar, Masoumeh; Edraki, Najmeh; Damghani, Tahereh; Moosavi, Fatemeh; Mohabbati, Maryam; Alipour, Alireza; Pirhadi, Somayeh; Saso, Luciano; Khabnadideh, Soghra; Firuzi, Omidreza.
Afiliação
  • Divar M; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Edraki N; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Damghani T; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Moosavi F; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Mohabbati M; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Alipour A; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Pirhadi S; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Saso L; Department of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University of Rome, P. le Aldo Moro 5, Rome, Italy.
  • Khabnadideh S; Pharmaceutical Sciences Research center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: khabns@sums.ac.ir.
  • Firuzi O; Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: firuzio@sums.ac.ir.
Bioorg Med Chem ; 90: 117367, 2023 07 15.
Article em En | MEDLINE | ID: mdl-37348260

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia / Antineoplásicos Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia / Antineoplásicos Idioma: En Ano de publicação: 2023 Tipo de documento: Article